| The Molecular Imaging Research of F-18 Labeled DX600 PET Probe (NCT04542863) | Peking University Cancer Hospital & Institute | 2020-09-11 |
| Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer (NCT04526470) | Seoul National University Bundang Hospital | 2020-09-01 |
| Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors (NCT04569916) | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2020-09-01 |
| Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas (NCT04407741) | Chinese PLA General Hospital | 2020-09-01 |
| Immune Resistance Interrogation Study (NCT04243720) | University Health Network, Toronto | 2020-08-26 |
| PRECISE CURATE.AI Pilot Clinical Trial (NCT04522284) | National University Hospital, Singapore | 2020-08-20 |
| Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies (NCT04305249) | Antengene Therapeutics Limited | 2020-08-15 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types (NCT04300556) | Eisai Inc. | 2020-08-06 |
| Phase I Study in Advanced Malignancies With 5-ALA (NCT04381806) | Fox Chase Cancer Center | 2020-07-30 |
| Study of GNX102 in Patients With Advanced Solid Tumors (NCT04250597) | GlycoNex, Inc. | 2020-07-29 |
| ONO-7913 Phase I Study (ONO-7913) (NCT04403308) | Ono Pharmaceutical Co., Ltd. | 2020-07-28 |
| A Feasibility Study for the Use of Multispectral Optoacoustic Tomography in the Detection of Tumors (NCT04365413) | University of Oklahoma | 2020-07-22 |
| HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies (NCT03906643) | Herbert Lyerly | 2020-07-15 |
| A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors (NCT04511871) | Shanghai PerHum Therapeutics Co., Ltd. | 2020-07-09 |
| A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer (NCT04419623) | Telios Pharma, Inc. | 2020-07-09 |
| Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors (NCT05088070) | Shanghai Pharmaceuticals Holding Co., Ltd | 2020-07-02 |
| Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors (NCT04235101) | Byondis B.V. | 2020-06-22 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (NCT04101357) | BioNTech SE | 2020-06-19 |
| Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients (NCT04422457) | Peking University Cancer Hospital & Institute | 2020-06-13 |
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (NCT04074967) | Dan Zandberg | 2020-06-11 |
| A Study of Anti-VEGFR2 AK109 in Subjects With Advanced Solid Tumors (NCT04547205) | Akeso | 2020-06-06 |
| Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor (NCT04346381) | Jiangsu HengRui Medicine Co., Ltd. | 2020-06-05 |
| A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas (NCT04306224) | ImmuneOncia Therapeutics Inc. | 2020-06-05 |
| Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors (NCT04400383) | CARsgen Therapeutics Co., Ltd. | 2020-06-04 |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (NCT04301011) | Turnstone Biologics, Corp. | 2020-06-02 |
| Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer (NCT04360317) | Kyunghee University Medical Center | 2020-06-01 |
| INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (NCT03838042) | University Hospital Heidelberg | 2020-05-26 |
| Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (NCT04348916) | Oncorus, Inc. | 2020-05-20 |
| Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors (NCT04344795) | Tempest Therapeutics | 2020-05-06 |
| A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer Populations (NCT04905329) | Moscow Clinical Scientific Center | 2020-04-28 |
| Immunotherapy for the Treatment of Advanced Solid Tumor (NCT03658785) | Tongji Hospital | 2020-04-28 |
| A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor (NCT04802980) | Huabo Biopharm Co., Ltd. | 2020-04-28 |
| Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels (NCT04537715) | Epizyme, Inc. | 2020-04-23 |
| Precision Medicine for Patients With Identified Actionable Mutations (NCT04111107) | Wake Forest University Health Sciences | 2020-04-22 |
| Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 (NCT04347226) | Columbia University | 2020-04-16 |
| A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors (NCT04175847) | RemeGen Co., Ltd. | 2020-04-14 |
| A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions (NCT04363242) | Synermore Biologics Co., Ltd. | 2020-04-09 |
| The GCO-002 CACOVID-19 Cohort: a French Nationwide Multicenter Study of COVID-19 Infected Cancer Patients (NCT04397575) | Federation Francophone de Cancerologie Digestive | 2020-04-03 |
| A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors (NCT04413227) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2020-04-02 |
| Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations (NCT04258527) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-03-26 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation (NCT04280081) | Eli Lilly and Company | 2020-03-16 |
| A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy (NCT04300088) | Assistance Publique - Hôpitaux de Paris | 2020-03-10 |
| A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate SYD1875 (NCT04202705) | Byondis B.V. | 2020-02-28 |
| Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer (NCT04348643) | Chongqing Precision Biotech Co., Ltd | 2020-02-20 |
| ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors (NCT04205227) | ENB Therapeutics, Inc | 2020-02-18 |
| Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors (NCT04249843) | MapKure, LLC | 2020-02-17 |
| Machine Learning Model to Predict HOLS and Mortality After Discharge in Hospitalized Oncologic Patients (NCT05534178) | Vall d'Hebron Institute of Oncology | 2020-02-15 |
| Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (NCT03735095) | Roswell Park Cancer Institute | 2020-02-12 |
| MAX-10181 Given Orally to Patients With Advanced Solid Tumor (NCT04122339) | Maxinovel Pty., Ltd. | 2020-02-11 |
| Indocyanine Green (ICG) Guided Tumor Resection (NCT04084067) | St. Jude Children's Research Hospital | 2020-02-07 |
| Effect of PARP Inhibitors on Glomerular Filtration Rate (NCT04367467) | University of Pennsylvania | 2020-02-03 |
| Trial Comparing Parenteral Nutrition (PN) Using Eurotubes® vs. 2/3-chamber Bags in Subjects With Solid Tumors Requiring PN (PEKANNUSS) (NCT04105777) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2020-01-30 |
| QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management (NCT05626764) | Hospices Civils de Lyon | 2020-01-27 |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes (NCT04171700) | pharmaand GmbH | 2020-01-16 |
| A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin (NCT04059588) | Rockefeller University | 2020-01-16 |
| Tepotinib in Solid Tumors Harboring MET Alterations (NCT04647838) | Chungbuk National University Hospital | 2020-01-16 |
| Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor (NCT04214717) | Yantai Yuhuangding Hospital | 2019-12-31 |
| Study of NK Combined With Chemotherapy for Advanced Solid Tumor (NCT04214730) | Yantai Yuhuangding Hospital | 2019-12-31 |
| Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (NCT03991832) | University Health Network, Toronto | 2019-12-31 |
| Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions (NCT04071756) | Dana-Farber Cancer Institute | 2019-12-30 |
| A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies (NCT04172597) | Spectrum Pharmaceuticals, Inc | 2019-12-23 |
| A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. (NCT04209465) | Black Diamond Therapeutics, Inc. | 2019-12-19 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
| Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients (NCT04478916) | Lorenza Scotti | 2019-12-18 |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors (NCT04165772) | Memorial Sloan Kettering Cancer Center | 2019-12-11 |
| Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (NCT04198766) | Inhibrx Biosciences, Inc | 2019-12-10 |
| Phase 1 Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of ATOR-1017 (NCT04144842) | Alligator Bioscience AB | 2019-12-03 |
| The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor (NCT04179656) | Tianjin Medical University Second Hospital | 2019-12-01 |
| MAX-40279-01 in Patients With Advanced Solid Tumors (NCT04183764) | Maxinovel Pty., Ltd. | 2019-11-28 |
| PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (NCT03993379) | CytomX Therapeutics | 2019-11-20 |
| Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) (NCT03865082) | Idera Pharmaceuticals, Inc. | 2019-10-29 |
| A Study of LY3435151 in Participants With Solid Tumors (NCT04099277) | Eli Lilly and Company | 2019-10-28 |
| Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer. (NCT03944499) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2019-10-11 |
| SOFT- Stereotactic Ablative Radiotherapy of Infra-diaphragmatic Soft Tissue Metastases (NCT04407897) | Herlev Hospital | 2019-10-07 |
| Trial of DFP-14927 in Advanced Solid Tumors (NCT03943004) | Delta-Fly Pharma, Inc. | 2019-09-30 |
| Evaluation of AP-002 in Patients With Solid Tumors (NCT04143789) | Altum Pharmaceuticals INC | 2019-09-27 |
| Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) (NCT03980041) | Infinity Pharmaceuticals, Inc. | 2019-09-25 |
| Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors (NCT04096638) | invoX Pharma Limited | 2019-09-23 |
| PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin (NCT04021277) | EXACT Therapeutics AS | 2019-09-17 |
| Safety Study of SLC-391 in Subjects With Solid Tumors (NCT03990454) | SignalChem Lifesciences Corporation | 2019-09-17 |
| Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells (NCT04082910) | Chinese PLA General Hospital | 2019-09-15 |
| A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors (NCT04172506) | Akeso | 2019-09-10 |
| Durvalumab Long-Term Safety and Efficacy Study (NCT04078152) | AstraZeneca | 2019-09-05 |
| Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients (NCT04107311) | University Health Network, Toronto | 2019-09-05 |
| CD276 CAR-T for Patients With Advanced CD276+ Solid Tumors (NCT04691713) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2019-09-01 |
| Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors (NCT04111445) | Adagene Inc | 2019-08-29 |
| Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors (NCT03905538) | University of Texas Southwestern Medical Center | 2019-08-13 |
| Research for the Molecular Imaging of the PD-L1 Targeting Tracer (NCT04304066) | Peking University Cancer Hospital & Institute | 2019-08-06 |
| Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials (NCT04184869) | Acrotech Biopharma Inc. | 2019-08-05 |
| Evaluate Safety, Tolerability and Pharmacokinetics of HLX22 in Patients With Advanced Solid Tumors Overexpressing HER2 (NCT03916094) | Shanghai Henlius Biotech | 2019-07-31 |
| Evaluate Eribulin ORA in Subjects With Solid Tumors (NCT04013217) | Health Hope Pharma | 2019-07-29 |
| Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors (NCT04064359) | Oxford BioTherapeutics Ltd | 2019-07-25 |
| IMP4297 Food Effect Trial in Healthy Volunteers (NCT04057729) | Impact Therapeutics, Inc. | 2019-07-22 |
| QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers (NCT04050709) | ImmunityBio, Inc. | 2019-07-18 |
| A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (NCT03953235) | Gritstone bio, Inc. | 2019-07-18 |
| Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 (NCT03975387) | Taiho Oncology, Inc. | 2019-07-11 |
| Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor (NCT04013048) | Jiangsu HengRui Medicine Co., Ltd. | 2019-07-08 |
| A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors (NCT03970382) | PACT Pharma, Inc. | 2019-07-03 |
| Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC (NCT03989115) | Revolution Medicines, Inc. | 2019-07-02 |
| Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161 (NCT04228406) | Fujian Cosunter Pharmaceutical Co. Ltd | 2019-07-01 |